Gonadotropin-releasing hormone agonist (GnRH-a) can induce LH surge and trigger final oocyte maturation, providing an effective method for reducing OHSS risk in patients receiving a GnRH antagonist protocol or progestin-primed ovarian stimulation (PPOS) protocol (1, 2). The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.